A week earlier than expected, Astrazeneca plc has gained FDA approval to market Zurampic (lesinurad), a new drug for treating high levels of uric acid in the blood associated with gout when given together with xanthine oxidase inhibitors (XOIs). It's the 45th new molecular entity approved by the agency this year.